Search Results for "Drug Interactions"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for Drug Interactions. Results 191 to 200 of 281 total matches.
An EUA for Anakinra (Kineret) for COVID-19 (online only)
The Medical Letter on Drugs and Therapeutics • Dec 12, 2022 (Issue 1665)
of anakinra by breastfeeding women has
not been associated with adverse effects.2,13
DRUG INTERACTIONS — Use ...
The recombinant interleukin-1 (IL-1) receptor
antagonist anakinra (Kineret – Sobi) has been
granted an FDA Emergency Use Authorization
(EUA) for treatment of hospitalized adults with
confirmed COVID-19 pneumonia who require low- or
high-flow supplemental oxygen, are at risk of
progressing to severe respiratory failure, and are
likely to have elevated plasma levels of soluble
urokinase plasminogen activator receptor (suPAR).
Anakinra has been available in the US for years; it
is FDA-approved for multiple indications, including
rheumatoid arthritis. Assays for suPAR are...
Darolutamide (Nubeqa) for Prostate Cancer
The Medical Letter on Drugs and Therapeutics • Dec 16, 2019 (Issue 1587)
,
or cognitive disorders.
DRUG INTERACTIONS — Darolutamide is metabolized
primarily by CYP3A4, and to a lesser ...
The FDA has approved darolutamide (Nubeqa –
Bayer), an androgen receptor inhibitor, for oral
treatment of nonmetastatic castration-resistant
prostate cancer (nmCRPC). Darolutamide is the third
androgen receptor inhibitor to be approved for this
indication; apalutamide (Erleada) and enzalutamide
(Xtandi), which are also approved for use in patients
with metastatic castration-resistant prostate cancer
(mCRPC), were approved earlier.
Live Fecal Microbiota Oral Capsules (Vowst) for Prevention of CDI Recurrence
The Medical Letter on Drugs and Therapeutics • May 29, 2023 (Issue 1677)
INTERACTIONS — Vowst contains live bacterial
spores; concurrent administration of antibacterial
drugs ...
The FDA has approved Vowst (Seres Therapeutics/Nestle HealthScience), an oral capsule containing live
fecal microbiota spores, for prevention of additional
recurrences of Clostridioides difficile infection (CDI)
in adults. Vowst is the first orally administered
microbiota-based treatment to be approved for
this indication. A rectally-administered live fecal
microbiota-based suspension (Rebyota) was
approved in 2022 for the same indication. Neither
product is approved for acute treatment of CDI.
Med Lett Drugs Ther. 2023 May 29;65(1677):81-2 doi:10.58347/tml.2023.1677a | Show Introduction Hide Introduction
Melatonin for Insomnia in Children
The Medical Letter on Drugs and Therapeutics • Jun 29, 2020 (Issue 1601)
of melatonin that occur at the onset of puberty.11,12
DRUG INTERACTIONS — Melatonin is metabolized ...
Over-the-counter products containing melatonin are
widely used as sleep aids in children and adults.
Lumateperone (Caplyta) for Schizophrenia
The Medical Letter on Drugs and Therapeutics • Jul 27, 2020 (Issue 1603)
an increased risk of death in elderly patients with
dementia-related psychosis.
DRUG INTERACTIONS ...
The FDA has approved lumateperone (Caplyta —
Intracellular Therapies), an oral second-generation
antipsychotic, for once-daily treatment of schizophrenia
in adults. It is the 13th second-generation antipsychotic
drug to be approved by the FDA for this indication.
Mirikizumab (Omvoh) for Ulcerative Colitis
The Medical Letter on Drugs and Therapeutics • Mar 18, 2024 (Issue 1698)
of mirikizumab
in breast milk or its effects on the breastfed infant or
milk production.
DRUG INTERACTIONS ...
The FDA has approved the interleukin (IL)-23
antagonist mirikizumab-mrkz (Omvoh – Lilly) for
treatment of moderately to severely active ulcerative
colitis (UC) in adults. Mirikizumab is the first selective
IL-23 antagonist to be approved for this indication.
Ustekinumab (Stelara), an IL-12/23 antagonist, was
approved for treatment of UC in 2019. The IL-23
antagonist risankizumab (Skyrizi) is approved for
treatment of Crohn's disease.
Med Lett Drugs Ther. 2024 Mar 18;66(1698):46-7 doi:10.58347/tml.2024.1698c | Show Introduction Hide Introduction
Teplizumab (Tzield) to Delay Onset of Type 1 Diabetes
The Medical Letter on Drugs and Therapeutics • Jan 09, 2023 (Issue 1667)
≥8 years old who have stage 2 type 1
diabetes. It is the first drug to become available ...
Teplizumab-mzwv (Tzield – Provention Bio), an anti-CD3 monoclonal antibody, has been approved by the
FDA to delay the onset of stage 3 type 1 diabetes
in patients ≥8 years old who have stage 2 type 1
diabetes. It is the first drug to become available in the
US that delays the onset of type 1 diabetes.
Med Lett Drugs Ther. 2023 Jan 9;65(1667):7-8 doi:10.58347/tml.2023.1667c | Show Introduction Hide Introduction
Metoclopramide Nasal Spray (Gimoti) for Diabetic Gastroparesis
The Medical Letter on Drugs and Therapeutics • Jan 11, 2021 (Issue 1615)
with epilepsy.
DRUG INTERACTIONS — Patients should avoid concomitant
use of metoclopramide and antipsychotics ...
The FDA has approved Gimoti (Evoke), a nasal
spray formulation of the dopamine-2 (D2) receptor
antagonist metoclopramide, for relief of symptoms in
adults with acute and recurrent diabetic gastroparesis.
Metoclopramide (Reglan, and generics) has been
available for years in conventional and orally-disintegrating
tablets and in an injectable formulation.
It is the only drug that is FDA-approved for treatment
of diabetic gastroparesis.
Remimazolam (Byfavo) for Short-Term Procedural Sedation
The Medical Letter on Drugs and Therapeutics • Feb 21, 2022 (Issue 1644)
and the sedative-hypnotic drug propofol
are commonly used for short-term procedural
sedation. Depending ...
The FDA has approved remimazolam (Byfavo – Acacia
Pharma), an ultra-short-acting IV benzodiazepine,
for induction and maintenance of sedation in adults
undergoing procedures of up to 30 minutes' duration.
Relyvrio for ALS
The Medical Letter on Drugs and Therapeutics • Nov 28, 2022 (Issue 1664)
studies, the combination was
associated with stillbirth.
DRUG INTERACTIONS ― Bile acid sequestrants (e.g ...
The FDA has approved Relyvrio (Amylyx), a fixed-dose
combination of sodium phenylbutyrate and
taurursodiol, for treatment of amyotrophic lateral
sclerosis (ALS). Sodium phenylbutyrate (Buphenyl,
and others) has been available by prescription
for years for treatment of urea cycle disorders.
Taurursodiol (tauroursodeoxycholic acid), a derivative
of ursodiol, is an over-the-counter bile acid
supplement claimed to have neuroprotective
benefits. Relyvrio is the third drug to be approved
in the US for treatment of ALS; riluzole (Rilutek, and
others) and edaravone (Radicava, Radicava...